Clinical Investigation of Plasma Copeptin Level on Major Adverse Cardiovascular Event in Patients With Acute ST-segment Elevation Myocardial Infarction During Hospitalization

Objective: To explore the clinical value of plasma copeptin level on major adverse cardiovascular event(MACE) occurrence in patients with acute ST-segment elevation myocardial infarction(STEMI) during hospitalization.Methods: Our research included 2 groups: STEMI group, n=80 and Control group, n=80 patients with stable coronary artery disease(CAD). All patients were treated in our hospital from 2012-06 to 2014-06. Plasma level of copeptin was detected by ELISA, other relevant examinations were conducted to study the MACE occurrence in STEMI patients.Results: Plasma copeptin level in STEMI group(523.26 ± 142.69) pg/ml was higher than that in Control group(345.25 ± 89.36) pg/ml, P0.05. In STEMI group, there were 28/80(35%) patients suffered from MACE, compared with non-MACE patients, they had increased plasma copeptin, cardiac muscle protein Ⅰ(cTnI), kinase isoenzyme(CK-MB) and left ventricular ejection fraction(LVEF), P0.05. Multivariate regression analysis indicated that plasma copeptin, cTnI and LVEF were the independent risk factors for MACE occurrence. According to occurred area under the curve, compared with cTnI and CK-MB, plasma copeptin level had the higher predictive value to judge the ROC, positive/negative possibility, sensitivity and specificity for MACE occurrence in STEAMI patients, P0.05.Conclusion: Plasma copeptin level could effectively predict MACE occurrence in patients with acute STEMI during hospitalization, it may predict their prognosis at certain point.